Cargando…
Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma
In relapsed and refractory multiple myeloma (RRMM), there are few treatment options once patients progress from the established standard of care. Several bispecific T-cell engagers (TCE) are in clinical development for multiple myeloma (MM), designed to promote T-cell activation and tumor killing by...
Autores principales: | Abrams, R. E., Pierre, K., El-Murr, N., Seung, E., Wu, L., Luna, E., Mehta, R., Li, J., Larabi, K., Ahmed, M., Pelekanou, V., Yang, Z.-Y., van de Velde, H., Stamatelos, S. K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243109/ https://www.ncbi.nlm.nih.gov/pubmed/35768621 http://dx.doi.org/10.1038/s41598-022-14726-5 |
Ejemplares similares
-
T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023) -
Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2022) -
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023) -
Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody
por: Harwardt, Julia, et al.
Publicado: (2023) -
Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture
por: Bogen, Jan P., et al.
Publicado: (2021)